Contraindications: Do not use Tamoxifen Citrate if you have a known hypersensitivity to Tamoxifen or any tablet excipient. Contraindicated in individuals with a history of thromboembolic events, including deep vein thrombosis or pulmonary embolism. Not indicated for use in biological females, individuals under 18, or those with active hepatic impairment. Concurrent use with strong CYP2D6 inhibitors (e.g. certain antidepressants) reduces Tamoxifen activation to active metabolites and should be avoided.
Side Effects: Reported adverse effects include hot flashes, mood fluctuation, temporary visual disturbances, and mild nausea — the last of which is often resolved by timing the tablet with a meal rather than on a completely empty stomach. Less common: reduced libido during the PCT window, transient lipid alterations, and headache. Ocular side effects (blurred vision, visual field changes) warrant immediate medical evaluation and protocol suspension.
Monitoring: Baseline and mid-protocol serum panels are strongly advisable: total testosterone, LH, FSH, estradiol, and a full lipid profile at minimum. Liver enzyme screening (ALT, AST) is prudent for protocols exceeding four weeks. Report any visual changes, leg swelling, or unusual shortness of breath to a physician without delay.
PCT: Tamoxifen Citrate is a SERM for use under the supervision of a qualified physician. It is not a substitute for medical evaluation of androgen-related endocrine suppression. Self-administration carries inherent risk; this product is not intended for human therapeutic use outside of jurisdictions where it is licensed for that purpose.